JP2025500841A5 - - Google Patents

Info

Publication number
JP2025500841A5
JP2025500841A5 JP2024535342A JP2024535342A JP2025500841A5 JP 2025500841 A5 JP2025500841 A5 JP 2025500841A5 JP 2024535342 A JP2024535342 A JP 2024535342A JP 2024535342 A JP2024535342 A JP 2024535342A JP 2025500841 A5 JP2025500841 A5 JP 2025500841A5
Authority
JP
Japan
Prior art keywords
composition
oea
subject
composition according
manufacture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024535342A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025500841A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/081372 external-priority patent/WO2023114722A1/en
Publication of JP2025500841A publication Critical patent/JP2025500841A/ja
Publication of JP2025500841A5 publication Critical patent/JP2025500841A5/ja
Pending legal-status Critical Current

Links

JP2024535342A 2021-12-13 2022-12-12 オレオイルエタノールアミドの生物学的に利用可能な製剤による肝臓脂肪変性の治療方法 Pending JP2025500841A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163265314P 2021-12-13 2021-12-13
US63/265,314 2021-12-13
PCT/US2022/081372 WO2023114722A1 (en) 2021-12-13 2022-12-12 Method of treating liver steatosis with bioavailable formulation of oleoylethanolamide

Publications (2)

Publication Number Publication Date
JP2025500841A JP2025500841A (ja) 2025-01-15
JP2025500841A5 true JP2025500841A5 (https=) 2025-12-19

Family

ID=86773562

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024535342A Pending JP2025500841A (ja) 2021-12-13 2022-12-12 オレオイルエタノールアミドの生物学的に利用可能な製剤による肝臓脂肪変性の治療方法

Country Status (8)

Country Link
US (1) US20250041249A1 (https=)
EP (1) EP4447950A1 (https=)
JP (1) JP2025500841A (https=)
KR (1) KR20240134319A (https=)
CN (1) CN118900687A (https=)
AU (1) AU2022416432A1 (https=)
CA (1) CA3242396A1 (https=)
WO (1) WO2023114722A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4573920A1 (en) * 2023-12-22 2025-06-25 Centre National de la Recherche Scientifique Texturizing complex comprising oleoylethanolamide and at least one fatty substance

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102579413A (zh) * 2011-01-14 2012-07-18 傅瑾 油酰乙醇胺及其衍生物的新用途
US12383502B2 (en) * 2017-04-13 2025-08-12 Pharmako Biotechnologies Pty Limited Cold-water-dispersible chemical delivery system
US10702487B2 (en) * 2017-08-19 2020-07-07 Frimline Private Limited Pharmaceutical composition for prevention of diet induced obesity

Similar Documents

Publication Publication Date Title
CN102088978B (zh) 血脂异常症的改善或治疗药
CN105120872B (zh) 包含15-hepe的组合物以及其使用方法
JPWO2016117057A1 (ja) ω3脂肪酸の自己乳化組成物
JP2019048843A5 (https=)
WO2015008848A1 (ja) ω3脂肪酸の自己乳化組成物
TW200816934A (en) Quercetin-containing compositions
RU2001134300A (ru) Фармацевтические и пищевые композиции, содержащие незаменимые жирные кислоты и гомоцистеин-понижающие агенты
TW200816985A (en) Methods for buccal, lingual or sublingual dosing regimens of epinephrine for the treatment of allergic emergencies
US20140088047A1 (en) Use of long chain polyunsaturated fatty acid derivatives to treat sickle cell disease
HUE029677T2 (hu) Készítmények centrálisan mediált émelygés és hányás kezelésére
RU2761967C2 (ru) Способ лечения, включающий пероральное или желудочное введение эдаравона
JP2021509395A5 (https=)
IL303900A (en) Drugs, therapeutic combinations and methods for preventing viral and microbial infections and their sequelae
CN1514725B (zh) 包含脂肪酶抑制剂和蔗糖脂肪酸酯的药物组合物
HRP20192189T1 (hr) Doziranja i terapijske primjene l-4-klorokinurenina
JP2025500841A5 (https=)
CN107847477A (zh) 包含15‑氧代‑epa或15‑氧代‑dgla的组合物及其制备和使用方法
JP2016505050A5 (https=)
JP7206223B2 (ja) パーキンソン病の予防および/または支持治療処置のための物質
JP2019147805A (ja) ω3脂肪酸の自己乳化組成物
JP4850821B2 (ja) リパーゼ阻害物質の使用
JP2009539969A (ja) メラトニン成分及びフラバノール成分を含む組成物及びキット
CN110461325A (zh) 包括口服或胃部施用依达拉奉的治疗
JP2019510745A5 (https=)
WO2004028549A1 (en) A coixenolide capsules for treating prostate disease